Episode 19: A Between the Biotech Waves Conversation with JeanFrancois Formela, Partner at Atlas Venture & multi-biotech company founder
Between the Biotech Waves
00:00
Is CRISPR-Cas9 Really a Drug?
I think I'm not quite an, I don't have a super original view. We've seen a tremendous growth in the area of genome editing where, you know, CRISPR-Cas9 is either used as the kind of primary targeting moiety to a region of DNA. And then you've got other catalytic domains, or we've seen growth into other areas above and beyond sort ofCRISPR-based systems. If we can reduce that to practice, which I think we're well on the way of doing, it's going to be really exciting. You'll see people with rare disease being able to cure them permanently. It's like science fiction at its most basic level
Transcript
Play full episode
